ONA THERAPEUTICS
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
ONA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science
Founded:
2019-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.ona-therapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
31.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Global Site Tag Sitelinks Search Box Yoast WordPress SEO Plugin Google Maps
Current Advisors List
Current Employees Featured
Founder
Investors List
Fund+
Fund+ investment in Series A - Ona Therapeutics
Bpifrance
Bpifrance investment in Series A - Ona Therapeutics
Asabys Partners
Asabys Partners investment in Series A - Ona Therapeutics
Ysios Capital
Ysios Capital investment in Series A - Ona Therapeutics
Alta Life Sciences
Alta Life Sciences investment in Series A - Ona Therapeutics
Asabys Partners
Asabys Partners investment in Seed Round - Ona Therapeutics
Official Site Inspections
http://www.ona-therapeutics.com
- Host name: box5466.bluehost.com
- IP address: 162.241.217.75
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Ona Therapeutics"
Ona Therapeutics | Home Page
ONA THERAPEUTICS, SL, declares to have implemented the necessary technical and organizational security measures that guarantee the security of the data and prevent its …See details»
Ona Therapeutics - Crunchbase Company Profile & Funding
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded …See details»
ONA Therapeutics - LinkedIn
ONA Therapeutics Biotechnology Research Barcelona, Catalonia 7,545 followers First-in-class ADCs tailor designed to attack advanced cancerSee details»
Ona Therapeutics - Company Profile
Ona Therapeutics. Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner …See details»
Home - Ona Therapeutics
We develop novel therapies against metastatic cancer 01 about US. Ona Therapeutics is a biotech company, spin-off of ICREA and IRB, specialized in the discovery and development of therapeutic biologics targeting tumor metastatic …See details»
Ona Therapeutics | Ona Therapeutics Strengthens Leadership …
Feb 19, 2025 Ona Therapeutics (“Ona”), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key leadership appointments to support …See details»
Ona Therapeutics - Funding, Financials, Valuation & Investors
Ona Therapeutics is focused on the discovery and development of therapeutic biologics to treat metastatic cancer. New. Resources. Advanced Search. Start Free Trial . ... How much funding …See details»
Ona Therapeutics - VentureRadar
Bicara Therapeutics USA Privately Held Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the targeted therapy …See details»
Ona Therapeutics - Asabys Partners
Ona Therapeutics Biotech company located in the Barcelona Science Park (PCB), specializes in the development of first-in-class antibody-drug conjugates (ADCs) for advanced breast cancer and beyond. The company has identified …See details»
Ona Therapeutics - IRB Barcelona
Ona Therapeutics was launched in 2019 and is specialised in the discovery and development of therapeutic biologics targeting tumour metastasis-initiating cells and lipid metabolism. This therapeutic approach has the potential to prevent …See details»
Ona Therapeutics | The Pharmaletter
Ona Therapeutics is a biotechnology company founded in 2019 as a spin-off from ICREA and the Institute for Research in Biomedicine (IRB) Barcelona. The company specializes in developing …See details»
Ona Therapeutics strengthens leadership team | The Pharmaletter
Feb 19, 2025 Barcelona, Spain-based biotech Ona Therapeutics today announced key leadership appointments to support its rapid growth and pipeline advancement. Dr Aleix Prat, …See details»
Ona Therapeutics Company Information - Funding, Investors, and …
The company Ona Therapeutics has raised a total of $35.65m in funding over 2 rounds. Key Insights: Series A: $33.97m; Seed: $1.68m; 2019. Ona Therapeutics Seed (2019, $1M) …See details»
ONA Therapeutics Strengthens Scientific Leadership Team
Oct 21, 2021 ONA THERAPEUTICS, SL, declares to have implemented the necessary technical and organizational security measures that guarantee the security of the data and prevent its …See details»
Ona Therapeutics Strengthens Leadership Team to Accelerate First …
Feb 19, 2025 Valerie Vanhooren, Ph.D., Co-Founder and Chief Executive Officer at Ona Therapeutics, said: "ADCs have transformed cancer treatment; however, the technology has …See details»
Ona Therapeutics SL (Ona Therapeutics SL) - 药物管线_专利_临床 …
BARCELONA, Spain, Dec. 18, 2023 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), a global biotech company focusing on the discovery and …See details»
The IRB Barcelona spin-off Ona Therapeutics hits the road thanks …
Today Ona Therapeutics, the new IRB Barcelona spin-off, announced the close of a seed funding round of € 1.5M given by Sabadell Asabys, a fund managed by Asabys Partners and devoted …See details»
Biocytogen and Ona enter cancer ADC development deal
Dec 18, 2023 Ona Therapeutics CEO and co-founder Dr Valerie Vanhooren stated: “We look forward to evaluating Biocytogen’s proprietary antibodies for ADC uses. “We believe the …See details»
Ona’s €30m Series A round: directly targeting metastasis in cancer
Jul 2, 2020 Barcelona-based Ona Therapeutics has closed a €30m Series A financing round. This comes just over a year after securing a bridge loan from local venture capital company …See details»
Eterna Therapeutics Changes Name to Ernexa Therapeutics to
5 days ago --Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company’ s new name: Ernexa …See details»